JLK has secured domestic product certification for its artificial intelligence (AI) medical device that analyzes potential abnormalities during Alzheimer’s treatment using brain magnetic resonance imaging (MRI).
On Tuesday, JLK, a medical AI specialist firm, announced that its brain imaging analysis and monitoring platform, TRACEGENT-AD, received medical device certification from the Food and Drug Administration.
TRACEGENT-AD is an AI platform designed to analyze brain images of patients at risk of serious complications during neurological treatment, assisting medical professionals in patient monitoring.
The AI algorithm visualizes high and low-intensity signal areas in brain magnetic resonance imagings (MRIs), providing quantitative data on lesions, including their number, diameter, and volume. It can also compare MRIs taken at different times to track lesion changes.
With the advent of anti-amyloid antibody treatments that target brain amyloid beta in Alzheimer’s therapy, early detection of potential side effects has become crucial.
A notable side effect, amyloid-related imaging abnormalities (ARIA), can manifest as brain edema or hemorrhage on MRIs. As some patients may be asymptomatic, regular MRI monitoring is vital for those receiving anti-amyloid treatments.
The increasing number of prescriptions and patients is expected to drive up demand for repeated MRI scans and image interpretation. JLK believes its AI technology, which rapidly and consistently analyzes multiple imaging sessions, can significantly reduce the monitoring workload for medical staff.
Leveraging this product certification, the company aims to expand partnerships with domestic medical institutions and validate its product’s effectiveness in clinical settings. JLK’s strategy involves applying its medical imaging AI expertise and commercialization experience from stroke care to address degenerative brain diseases like Alzheimer’s.
JLK is also pursuing international market expansion. The company plans to package its solutions into a comprehensive offering and navigate regulatory approval processes with agencies such as the U.S. Food and Drug Administration (FDA).
A JLK spokesperson stated that as dementia treatment prescriptions increase, the need for frequent MRI scans and precise image analysis will grow. It’s committed to expanding collaborations with domestic medical institutions while expediting regulatory approvals with agencies like the FDA.